Abbott (ABT) reached $115.29 at the closing of the latest trading day, reflecting a +2.74% change compared to its last close.
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alliance Wealth Advisors LLC UT lowered its stake in Abbott Laboratories (NYSE: ABT) by 30.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,225 shares of the healthcare product maker's stock after selling 8,086 shares during the quarter. Alliance
| Pharmaceuticals Industry | Healthcare Sector | Robert Ford CEO | XFRA Exchange | US0028241000 ISIN |
| US Country | 114,000 Employees | 13 Feb 2026 Last Dividend | 2 Jan 2013 Last Split | 13 Jan 1978 IPO Date |
Abbott Laboratories is a global healthcare company that engages in the discovery, development, manufacturing, and sale of a wide range of health care products. With its foundation laid in 1888, and headquartered in North Chicago, Illinois, the company has established a significant presence worldwide. Abbott operates across four main sectors: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, catering to a diverse range of healthcare needs from generic pharmaceuticals to advanced medical devices.
Abbott Laboratories offers a comprehensive portfolio of products and services across various healthcare domains: